Search results
British drugmaker seeks to acquire D.C. biotech for $466M - Washington Business Journal
The Business Journals· 4 days agoVanda said at the time Future Pak’s proposal “substantially undervalues the company, creates...
Esprit Execs Address Widespread Downsizings and the Brand’s Future
WWD via Yahoo Finance· 3 days agoTop officials tell WWD that this week's speculation about New York operations on Varick Street...
The Memorial and LIV Houston are the final stops before the US Open
Associated Press via Yahoo Sports· 7 days agoSingapore. Notes: This is the first time LIV Golf is playing in Texas. It returns at the end of the...
Cricket and biryani go together like baseball and hot dogs
WUSF 89.7· 3 days agoThe most anticipated game of the Cricket World Cup may be the Pakistan-India game on Sunday. The...
US cricket stuns Pakistan in a thrilling 'super over' match, nabs second tournament victory
USA TODAY Sports via Yahoo Sports· 4 days agoHISTORY...Cup just *feels* like the perfect batshit American thing to happen doesn’t it…#PakvsUSA —...
Seventh Circuit Finds Access or Disclosure Exclusion Bars Coverage for BIPA Claims
The National Law Review· 6 days agoOn May 17, 2024, the U.S. Court of Appeals for the Seventh Circuit affirmed an Illinois federal...
Tindley Accelerated Schools’ former CEO charged with defrauding the charter network
Indianapolis Star via Yahoo News· 7 days agoThe school was asked not to disclose any information about the law enforcement investigation until ...
Vanda Pharmaceuticals stock: why is it up 20% on Thursday?
Invezz· 5 days agoThe U.K. based company is willing to pay $8.0 per share for Vanda Pharmaceuticals that translates to...
Today in Sports - Novak Đoković wins his men’s record 23rd Grand Slam singles title
Associated Press· 18 hours ago1898 — Willie Simms becomes the only African American jockey to win the Preakness Stakes when he...
Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal - Vanda Pharma...
Benzinga· 5 days agoLtd worth $8 per share, representing a total cash consideration of $466 million. In May, Cycle launched its sixth drug product in the U.S. market. In April, Vanda rejected ...